Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

Background Non-small cell lung cancer (NSCLC) patients treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) almost always acquire resistance, and the development of novel techniques analyzing circulating tumor DNA (ctDNA) have made it possible for liqui...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in oncology 2021-02, Vol.11, p.621992-621992, Article 621992
Hauptverfasser:	Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-an
Format:	Artikel
Sprache:	eng
Schlagworte:	drug resistance epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gene sequencing Life Sciences & Biomedicine liquid biopsy non-small cell lung cancer Oncology Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!